Patent · US Expired

Nucleoside analogs

US6248878A · kind A · utility

92Cited by

6References

16Claims

0Family size

Assignee

Ribozyme Pharmaceuticals, Inc. · US

Inventors

Jasenka Matulic-Adamic · Boulder, US
Leonid Beigelman · San Mateo, US
Alexander Karpeisky · Aurora, US

Key dates

Filing date	Nov 21, 1997
Grant date	Jun 19, 2001
Priority date	—
Expiry date	Nov 21, 2017

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/322
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Novel nucleoside analogs, such as 3-(.beta.-D-Ribofuranosyl)-2-fluoropyridine, 3-(.beta.-D-Ribofuranosyl)-pyridin-2-one, 3-(.beta.-D-Ribofuranosyl)-pyridin-2-(4-nitrophenylethyl)-one, 3-(.alpha.-D-Ribofuranosyl)-2-fluoropyridine, 5-(.beta.-D-Ribofuranosyl)-2-bromopyridine, 5-(.alpha.-D-Ribofuranosyl)-2-bromopyridine, 5-(.beta.-D-Ribofuranosyl)-pyridin-2-one, 5-(.alpha.-D-Ribofuranosyl)-pyridin-2-one, 5-(.beta.-D-Ribofuranosyl)-2-aminopyridine, 5-(.beta.-D-Ribofuranosyl)-pyridin-2-(4-nitrophenylethyl)-one, and 5-(.alpha.-D-Ribofuranosyl)-2-aminopyridine; process for their synthesis and incorporation into polynucleotides.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.